Foundations Investment Advisors LLC Reduces Holdings in Cencora, Inc. $COR

Foundations Investment Advisors LLC decreased its position in shares of Cencora, Inc. (NYSE:COR) by 24.9% in the 2nd quarter, Holdings Channel reports. The fund owned 2,263 shares of the company’s stock after selling 750 shares during the quarter. Foundations Investment Advisors LLC’s holdings in Cencora were worth $679,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Kingsview Wealth Management LLC raised its position in shares of Cencora by 21.1% in the first quarter. Kingsview Wealth Management LLC now owns 2,620 shares of the company’s stock valued at $728,000 after purchasing an additional 457 shares during the period. Private Advisor Group LLC grew its stake in Cencora by 9.2% in the 1st quarter. Private Advisor Group LLC now owns 6,796 shares of the company’s stock valued at $1,890,000 after buying an additional 572 shares in the last quarter. Kestra Private Wealth Services LLC raised its holdings in Cencora by 10.9% during the 1st quarter. Kestra Private Wealth Services LLC now owns 10,750 shares of the company’s stock valued at $2,989,000 after acquiring an additional 1,058 shares during the period. J.W. Cole Advisors Inc. raised its holdings in Cencora by 49.3% during the 1st quarter. J.W. Cole Advisors Inc. now owns 6,018 shares of the company’s stock valued at $1,674,000 after acquiring an additional 1,987 shares during the period. Finally, Obermeyer Wealth Partners lifted its position in shares of Cencora by 1.3% during the first quarter. Obermeyer Wealth Partners now owns 2,724 shares of the company’s stock worth $758,000 after acquiring an additional 36 shares in the last quarter. 97.52% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other news, Chairman Steven H. Collis sold 31,350 shares of the company’s stock in a transaction on Tuesday, September 16th. The shares were sold at an average price of $289.86, for a total value of $9,087,111.00. Following the completion of the sale, the chairman owned 305,913 shares of the company’s stock, valued at approximately $88,671,942.18. This represents a 9.30% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Robert P. Mauch sold 5,097 shares of the stock in a transaction on Monday, October 20th. The shares were sold at an average price of $326.80, for a total transaction of $1,665,699.60. Following the transaction, the chief executive officer directly owned 37,940 shares in the company, valued at approximately $12,398,792. This represents a 11.84% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 41,544 shares of company stock valued at $12,230,941. Company insiders own 10.80% of the company’s stock.

Cencora Stock Down 0.9%

COR opened at $361.80 on Wednesday. The business’s fifty day simple moving average is $323.97 and its 200 day simple moving average is $303.25. Cencora, Inc. has a 52 week low of $223.92 and a 52 week high of $369.00. The company has a quick ratio of 0.53, a current ratio of 0.90 and a debt-to-equity ratio of 3.64. The stock has a market cap of $70.14 billion, a PE ratio of 37.22, a P/E/G ratio of 1.56 and a beta of 0.63.

Cencora (NYSE:COR) last posted its quarterly earnings data on Wednesday, November 5th. The company reported $3.84 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.79 by $0.05. The firm had revenue of $83.73 billion during the quarter, compared to analysts’ expectations of $83.36 billion. Cencora had a return on equity of 267.36% and a net margin of 0.60%.The company’s revenue for the quarter was up 5.9% compared to the same quarter last year. During the same period in the prior year, the business earned $3.34 EPS. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. As a group, research analysts expect that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 14th will be paid a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a dividend yield of 0.7%. This is a boost from Cencora’s previous quarterly dividend of $0.55. The ex-dividend date of this dividend is Friday, November 14th. Cencora’s payout ratio is 30.19%.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the company. Wall Street Zen upgraded Cencora from a “hold” rating to a “buy” rating in a research note on Saturday, November 8th. TD Cowen upped their price target on Cencora from $350.00 to $400.00 and gave the company a “buy” rating in a research report on Monday, November 10th. Evercore ISI set a $400.00 price target on shares of Cencora and gave the stock an “outperform” rating in a report on Thursday, November 6th. JPMorgan Chase & Co. boosted their price objective on shares of Cencora from $344.00 to $417.00 and gave the company an “overweight” rating in a research note on Tuesday, November 11th. Finally, UBS Group increased their target price on shares of Cencora from $380.00 to $415.00 and gave the stock a “buy” rating in a research note on Friday, November 7th. Nine research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $371.09.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.